Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 9/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131252 | 1.00 | PRMT5 (0.41) | PRMT5ALOX5BTKWDR5KDM4E | |
| SCHEMBL1131560 | 0.91 | ALOX5 (0.43) | ALOX5BTKKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1131479 | 0.91 | ALOX5 (0.43) | ALOX5BTKKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1131706 | 0.89 | ALOX5 (0.42) | ALOX5BTKWDR5KDM4EKMT2A | |
| SCHEMBL1131710 | 0.89 | ALOX5 (0.42) | ALOX5BTKWDR5KDM4EKMT2A | |
| SCHEMBL1131258 | 0.83 | ALOX5 (0.41) | PRMT5ALOX5BTKKDM4EKMT2A | |
| SCHEMBL1131573 | 0.81 | PTPN1 (0.44) | ALOX5BTKKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1131481 | 0.81 | PTPN1 (0.44) | ALOX5BTKKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1131416 | 0.79 | PTPN1 (0.48) | PRMT5ALOX5 | |
| SCHEMBL1131692 | 0.79 | PTPN1 (0.48) | PRMT5ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | claimed |
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | disclosed |